Recent Updates
Recently added Catalysts
DTIL Positive Sentiment

Precision BioSciences Announces Oral Presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Monday, February 24, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Precision BioSciences announced its participation in the 2025 Muscular Dystrophy Association Clinical & Scientific Conference. The company focuses on in vivo gene editing therapies using its proprietary ARCUS platform. This presentation highlights their ongoing commitment to advancing gene editing technologies.
Price reaction · baseline $5.59 (2025-02-24T18:00:00.000Z) · hit during market hours · clean, no other DTIL news in the window
day 0 close · peak
+0.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Precision BioSciences is actively participating in a significant conference.
  • The company is advancing its gene editing therapies.
  • The ARCUS platform shows promise in developing innovative treatments.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer

Full Press Release Details

DURHAM, N.C. –(BUSINESS WIRE)–Feb. 24, 2025– Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, including gene elimination, gene insertion, and gene excision programs, today

Frequently Asked Questions

What is the focus of Precision BioSciences?

Precision BioSciences focuses on developing in vivo gene editing therapies.

What platform does Precision BioSciences use?

The company utilizes its proprietary ARCUS platform for gene editing.

When is the MDA Clinical & Scientific Conference?

The MDA Clinical & Scientific Conference is scheduled for 2025.

What type of therapies is Precision BioSciences developing?

They are developing therapies for gene elimination, insertion, and excision.

ShareAdd on Google
Tags: DTIL Viatris Investor Conferences Healthcare Precision BioSciences MDA Conference gene editing ARCUS platform
Last updated: Feb 24, 2025

Biotech snapshot

Cash runway
$88M liquidity · $4M/mo burn
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-TPhase 1
Advanced Lung Cancer →

Catalyst track record

+24%
best trade around DTIL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for DTIL.

See every catalyst's timing & PoA →